Suscribirse

Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension - 25/08/11

Doi : 10.1016/j.amjmed.2004.01.024 
Cathy B Spranger, MPH a, c, Andrea J Ries, PharmD d, Carrie A Berge, PharmD e, Nina B Radford, MD b, Ronald G Victor, MD b, c,
a Department of Internal Medicine, Division of Cardiology, Athens, Texas USA 
b Department of Internal Medicine, Division of Hypertension, Athens, Texas USA 
c Donald W. Reynolds Cardiovascular Clinical Research Center, Athens, Texas USA 
d University of Texas Southwestern Medical Center, Dallas; Pfizer, Inc., Athens, Texas, USA 
e Department of Pharmacy, Parkland Health and Hospital System, Dallas, Texas, USA 

*Requests for reprints should be addressed to Ronald G. Victor, MD, Hypertension Division, University of Texas Southwestern Medical Center, Room J4.134, 5323 Harry Hines Boulevard, Dallas, Texas 75235-8586

Abstract

Purpose

Hypertension remains uncontrolled in the majority of affected patients despite treatment. Our goal was to identify specific action items in the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) guidelines that are not being translated into clinical practice.

Methods

We transformed the major JNC VI tables into a chart review instrument that was used to retrospectively analyze the medical records of 249 patients with newly diagnosed hypertension who had been followed for 18 months at one of six community-based primary care clinics.

Results

The practices of physicians deviated from the guidelines in several ways. Hypertension was staged initially on a single blood pressure recording in 85% (n = 212) of patients. No electrocardiogram was ordered for 89% (n = 221) of patients, while other mandatory laboratory tests were ordered for about 50%. After 18 months, 40% (72/179) of patients for whom prescription records were identified were still on monotherapy, and target blood pressure (<140/90 mm Hg) was achieved in only 33% (83/249) of patients. All of the 35 patients with diabetes received an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, but only 1.7 medications were prescribed per patient at study end.

Conclusion

In this clinic system, staging of blood pressure with multiple measurements, thorough assessment of global cardiovascular risk, and titration of multiple antihypertensive medications to achieve blood pressure goal are components of the JNC VI guidelines that are not well translated into clinical practice. Overcoming these practice defects will require innovative multilevel interventions.

El texto completo de este artículo está disponible en PDF.

Esquema


 This study was supported by funding from the Donald W. Reynolds Foundation; an unrestricted educational grant from Pfizer, Inc., New York, New York; and a research grant from Bristol-Myers Squibb, Princeton, New Jersey.


© 2004  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 117 - N° 1

P. 14-18 - juillet 2004 Regresar al número
Artículo precedente Artículo precedente
  • Thyroid disorders in chronic hepatitis C
  • Alessandro Antonelli, Clodoveo Ferri, Alessandro Pampana, Poupak Fallahi, Claudia Nesti, Martina Pasquini, Santino Marchi, Ele Ferrannini
| Artículo siguiente Artículo siguiente
  • Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology
  • Mary Cushman, Albert W Tsai, Richard H White, Susan R Heckbert, Wayne D Rosamond, Paul Enright, Aaron R Folsom

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.